Celularity (NASDAQ:CELU) Research Coverage Started at WBB Securities

WBB Securities initiated coverage on shares of Celularity (NASDAQ:CELUFree Report) in a research report report published on Monday, Marketbeat reports. The brokerage issued a moderate buy rating and a $6.00 price objective on the stock.

Separately, Wall Street Zen raised shares of Celularity to a “sell” rating in a report on Saturday, August 2nd.

Check Out Our Latest Report on CELU

Celularity Stock Performance

Celularity stock opened at $3.65 on Monday. The firm’s 50 day simple moving average is $2.63 and its 200 day simple moving average is $2.07. The firm has a market capitalization of $87.42 million, a PE ratio of -1.38 and a beta of 0.79. Celularity has a 1-year low of $1.00 and a 1-year high of $5.22. The company has a current ratio of 0.38, a quick ratio of 0.28 and a debt-to-equity ratio of 4.07.

Hedge Funds Weigh In On Celularity

Several institutional investors and hedge funds have recently made changes to their positions in CELU. Acadian Asset Management LLC bought a new position in shares of Celularity during the 1st quarter valued at $34,000. XTX Topco Ltd boosted its position in Celularity by 106.4% during the 2nd quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock valued at $42,000 after buying an additional 11,057 shares during the period. Bank of America Corp DE boosted its position in Celularity by 1,538.1% during the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock valued at $73,000 after buying an additional 35,023 shares during the period. Two Sigma Investments LP purchased a new stake in Celularity during the 4th quarter valued at $93,000. Finally, Valmark Advisers Inc. purchased a new stake in Celularity during the 2nd quarter valued at $98,000. Institutional investors own 19.02% of the company’s stock.

About Celularity

(Get Free Report)

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.

Further Reading

Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.